Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICT01 + aldesleukin
- Development stage
- Unknown
- Lead developer
- ImCheck Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
ICT01 + aldesleukin is a combination therapy composed of ICT01, a humanized monoclonal antibody that targets butyrophilin subfamily 3 member A (BTN3A), and aldesleukin, a recombinant interleukin-2 (IL-2) cytokine. ICT01 selectively activates γ9δ2 T cells via BTN3A, promoting anti-tumor immune responses. Aldesleukin (Proleukin) is a recombinant IL-2 that stimulates the proliferation and activation of T lymphocytes and natural killer (NK) cells, amplifying immune-mediated anti-tumor activity. The combination is being developed to enhance immune responses in advanced solid tumors and hematologic malignancies, under evaluation in phase 1/2 clinical studies for cancers such as metastatic colorectal cancer, melanoma, castration-resistant prostate cancer, ovarian cancer, and pancreatic ductal adenocarcinoma. The regimen is typically administered via intravenous (ICT01) and subcutaneous (aldesleukin) routes and is being investigated with or without pembrolizumab in clinical trials[1][3][6][7].
- Brand names
- Proleukin
- Other names
- Recombinant interleukin-2IL-2IL2IL 2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)BTN3A2 (Butyrophilin subfamily 3 member A2)BTN3A1 (Butyrophilin subfamily 3 member A1)BTN2A1 (Butyrophilin subfamily 2 member A1)BTN3A3 (Butyrophilin subfamily 3 member A3)
Beyond the preview
Go deeper on ICT01 + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICT01 + aldesleukin.